Research programme: Ig fusion GAIM dimers - Proclara Biosciences

Drug Profile

Research programme: Ig fusion GAIM dimers - Proclara Biosciences

Alternative Names: NPT 007; NPT 014; NPT 289

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator NeuroPhage Pharmaceuticals
  • Developer Proclara Biosciences
  • Class Recombinant fusion proteins
  • Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Protein aggregation inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyloidosis; Parkinson's disease

Most Recent Events

  • 07 Sep 2016 Preclinical development is still ongoing in Alzheimer's and Parkinson's disease in USA (Proclara pipeline, September 2016)
  • 07 Sep 2016 NeuroPhage Pharmaceuticals is now called Proclara Biosciences
  • 01 Sep 2016 Preclinical trials in Amyloidosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top